SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

ZNTL

ZENTALIS PHARMACEUTICALS
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the DENALI Part 2 topline data by year-end 2026 as a key catalyst; the current cash runway provides buffer, but future dilution risk remains if additional funding is needed post-2027.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.10
T+0 close · Mar 26, 2026 · via day close
Latest settled
+81.19%
T+60 · $3.81
Vs SPY
+65.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $2.10entry
  2. T+1 · 8mo ago +1.90%α +2.26% · $2.14
  3. T+5 · 8mo ago +28.10%α +24.23% · $2.69
  4. T+20 · 7mo ago +102.38%α +89.64% · $4.25
  5. T+60 · 5mo ago +81.19%α +65.12% · $3.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction in R&D and G&A expenses, with $245.9 million in cash providing a runway into late 2027. The company remains on track for key 2026 milestones, including dose confirmation in 1H 2026 and a topline readout from the DENALI Part 2 trial by year-end, which could support accelerated FDA approval of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer.

Key Financial Metrics

Revenue
$0.00
-100.0% YoY
EPS
$-1.91

Key Facts

  • Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, sufficient to fund operations into late 2027.
  • R&D expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, driven by lower clinical, lab, manufacturing, and personnel costs.
  • G&A expenses dropped to $37.7 million in 2025 from $87.1 million in 2024, largely due to a $47.1 million reduction in personnel expenses, including $40.8 million in non-cash stock-based compensation.
  • No revenue was recorded in 2025, compared to $67.4 million in licensing revenue in 2024 from a prior collaboration.
  • DENALI Part 2a enrollment completed; dose confirmation expected in 1H 2026, with topline data from Part 2 expected by end of 2026.
  • ASPENOVA Phase 3 trial design aligned with FDA; initiation expected in 1H 2026.

Financial Impact

Operating expenses reduced by $105.8 million YoY, improving cash preservation. However, revenue dropped to $0 in 2025 from $67.4 million in 2024.

cash runwayR&D expenseG&A expenserevenue

Risk Factors

  • No revenue in 2025; future depends entirely on azenosertib's clinical and regulatory success.
  • Prior revenue was non-recurring (licensing), making current business model unproven.
  • Clinical trial delays or negative data could significantly impact valuation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263392

Track record

18 reports on ZNTL

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026